2. Search Result
Search Result
Results for "

PF

" in MedChemExpress (MCE) Product Catalog:

611

Inhibitors & Agonists

1

Screening Libraries

8

Fluorescent Dye

2

Biochemical Assay Reagents

9

Peptides

47

Inhibitory Antibodies

11

Natural
Products

16

Recombinant Proteins

20

Isotope-Labeled Compounds

3

Antibodies

3

Click Chemistry

12

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13007
    PF-3758309
    5+ Cited Publications

    PF-03758309

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309
  • HY-12584
    PF-5190457

    PF-05190457

    		 GHSR Metabolic Disease Endocrinology
    PF-5190457 (PF-05190457) is a potent and selective ghrelin receptor inverse agonist with a pKi of 8.36 .
    PF-5190457
  • HY-108691
    PF-06465469
    2 Publications Verification

    		 Itk Btk CXCR PD-1/PD-L1 LAG-3 Cancer
    PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma .
    PF-06465469
  • HY-175747
    PF-07293893

    		AMPK Cardiovascular Disease
    PF-07293893 is an AMPKγ3 activator. PF-07293893 increases glycogen content, improves lipid oxidation, enhances mitochondrial biogenesis and promotes vascular repair. PF-07293893 is applicable to research related to heart failure .
    PF-07293893
  • HY-10032
    PF 477736
    4 Publications Verification

    PF 00477736

    		 Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK Cancer
    PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .
    PF 477736
  • HY-159657
    PF-07899895

    		Salt-inducible Kinase (SIK) Interleukin Related Inflammation/Immunology
    PF-07899895 (Compound 34) is a SIK inhibitor, with IC50 values of 1.2 nM, 0.9 nM, and 1.8 nM against SIK1, SIK2, and SIK3, respectively. PF-07899895 modulates the anti-inflammatory cytokine IL-10 in immune cells. PF-07899895 is applicable to research related to inflammatory diseases .
    PF-07899895
  • HY-111371
    PF-05180999

    PF-999

    		 Phosphodiesterase (PDE) Neurological Disease
    PF-05180999 (PF-999) is a phosphodiesterase 2A (PDE2A) inhibitor, with an IC50 of 1.6 nM.
    PF-05180999
  • HY-100873
    PF-1355
    3 Publications Verification

    PF-06281355

    		 Glutathione Peroxidase Cardiovascular Disease
    PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
    PF-1355
  • HY-14380
    PF-3845
    2 Publications Verification

    		 FAAH Autophagy Inflammation/Immunology Cancer
    PF-3845 is a potent, selective, irreversible and orally active inhibitor of fatty acid amide hydrolase (FAAH), with a Ki of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile. PF-3845 can reduce pain sensation, inflammation, and anxiety/depression without substantial effects on motility or cognition .
    PF-3845
  • HY-159648
    PF-07328948

    		Endogenous Metabolite Cardiovascular Disease
    PF-07328948 is an orally effective BDK (branch chain ketoacid dehydrogenase kinase) inhibitor, with IC50 of 110 nM. PF-07328948 acts as a BCKDH (branch chain ketoacid dehydrogenase) enzyme complex degrader to enhance BCAA (branch chain amino acid) catabolism. PF-07328948 improves metabolic and heart failure end points in rats .
    PF-07328948
  • HY-114182
    PF-06928215
    3 Publications Verification

    		 Cyclic GMP-AMP Synthase Inflammation/Immunology
    PF-06928215 is a cGAS (cyclic GMP-AMP Synthase) inhibitor with an IC50 of 4.9 μΜ. PF-06928215 has a high binding affinity of 0.2 μM (Kd) .
    PF-06928215
  • HY-120072
    PF-3450074
    5 Publications Verification

    PF-74

    		 HIV Infection
    PF-3450074 (PF-74) is a specifical inhibitor of HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle . CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.
    PF-3450074
  • HY-120789
    PF-06648671

    		γ-secretase Neurological Disease
    PF-06648671 is a novel, brain-penetrable, and orally active γ-secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease .
    PF-06648671
  • HY-115506
    PF-05105679

    		TRP Channel Neurological Disease
    PF-05105679, a chemical probe, is an orally active and selective TRPM8 antagonist with an IC50 of 103 nM. PF-05105679 has the potential for cold-related pain .
    PF-05105679
  • HY-103682
    PF-06726304
    1 Publications Verification

    		 Histone Methyltransferase Cancer
    PF-06726304 is a potent and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with Kis of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity .
    PF-06726304
  • HY-122616
    PF-06273340

    		Trk Receptor Neurological Disease
    PF-06273340 is a peripherally restricted pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, and TrkC receptors. PF-06273340 binds in a DFG-out conformation, targeting less conserved kinase ligand binding domain regions outside the ATP binding pocket. PF-06273340 exhibits anti-hyperalgesic and analgesic effects. PF-06273340 can be used for the research of pain .
    PF-06273340
  • HY-19985
    PF-06459988

    		EGFR Cancer
    PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer .
    PF-06459988
  • HY-113788
    PF-719

    		Pyk2 p38 MAPK Amyloid-β Neurological Disease Inflammation/Immunology
    PF-719 is a highly selective Pyk2 inhibitor with an IC50 value of 17 nM. PF-719 promotes the activation of LKB1 and p38 MAPK. PF-719 blocks synaptic deficits induced by Amyloid-beta oligomers and reverses the inhibition of long-term potentiation induced by β-amyloid oligomers. PF-719 can be used in research related to Alzheimer's disease and autoimmune diseases .
    PF-719
  • HY-117623
    PF-06685249

    PF-249

    		 AMPK Metabolic Disease
    PF-06685249 (PF-249) is a potent and orally active allosteric AMPK activator with an EC50 of 12 nM for recombinant AMPK α1β1γ1. PF-06685249 improves renal function in ZSF-1 rats with diabetic nephropathy. PF-06685249 can be used for diabetic nephropathy research .
    PF-06685249
  • HY-122026
    PF-04802367

    PF-367

    		 GSK-3 Neurological Disease
    PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively .
    PF-04802367
  • HY-120103
    PF-06649298
    1 Publications Verification

    		 Sodium Channel Metabolic Disease
    PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .
    PF-06649298
  • HY-11044
    PF-03654746 Tosylate

    		Histamine Receptor Neurological Disease Metabolic Disease Inflammation/Immunology
    PF-03654746 Tosylate is a potent, selective and brain-penetrant histamine H3 receptor antagonist. PF-03654746 Tosylate reduces allergen-induced nasal symptoms . PF-03654746 Tosylate has potential for treatment of human cognitive disorders, improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD) .
    PF-03654746 Tosylate
  • HY-101024
    PF-06263276

    		JAK STAT Inflammation/Immunology
    PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. PF-06263276 inhibits pSTAT3 and TYK2 pathway. PF-06263276 has a protective effect against ear skin inflammation .
    PF-06263276
  • HY-11028
    PF-02413873

    PF-2413873

    		 Progesterone Receptor Endocrinology
    PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal progesterone receptor (PR) antagonist, with a Ki of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo .
    PF-02413873
  • HY-138916
    PF-06672131

    		Biochemical Assay Reagents EGFR Others
    PF-06672131 is an alkynylated afatinib derivative and a small molecule probe that is reactive to cysteine. PF-06672131 is an inhibitor of epidermal growth factor receptor (EGFR) kinase that targets the ATP pockets of EGFR. PF-06672131 can be used for activity-based protein profiling studies .
    PF-06672131
  • HY-18862
    PF-03715455

    		p38 MAPK Inflammation/Immunology
    PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .
    PF-03715455
  • HY-108340
    PF-06767832

    		mAChR Neurological Disease
    PF-06767832 is a potent muscarinic M1 selective positive allosteric modulator (PAM), with the EC50 of 60 nM. PF-06767832 has good brain penetration .
    PF-06767832
  • HY-110325
    PF-04885614

    		Sodium Channel Neurological Disease
    PF-04885614 is a potent NaV1.8 inhibitor, extracted from patent US2018328915. PF-04885614 has potential for neurological and neurodevelopmental diseases treatment .
    PF-04885614
  • HY-122805
    PF-794

    		Ser/Thr Protease Neurological Disease
    PF-794 is a potent, selective and ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with an IC50 of 39 nM. PF-794 shows selective for the TNIK family. PF-794 reduces endogenous p120-catenin phosphorylation in cells. PF-794 can be used for teh study of psychiatric disorders .
    PF-794
  • HY-116625
    PF-04628935

    		GHSR Neurological Disease
    PF-04628935 (compound 10n) is a potent ghrelin receptor inverse agonist, with an IC50 of 4.6 nM. PF-04628935 exhibits oral bioavailability of 43% in rats and shows reasonable penetration into the brain. PF-04628935 can be used for stress and anxiety research .
    PF-04628935
  • HY-15691
    PF-04455242

    		Opioid Receptor mTOR Neurological Disease Metabolic Disease
    PF-04455242 is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-04455242 blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-04455242 promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-04455242 attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-04455242 can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .
    PF-04455242
  • HY-117048
    PF-4191834

    PF-04191834

    		 Lipoxygenase Inflammation/Immunology
    PF-4191834 (PF-04191834) is an orally active, noniron chelating, and non-redox inhibitor of the 5-Lipoxygenase (5-LOX) (IC50=229 nM), displays ~300-fold selectivity for 5-LOX over 12-LOX and 15-LOX, shows no activity toward the cyclooxygenase enzymes, and is effective in inflammation and pain .
    PF-4191834
  • HY-12788
    PF-04449613

    		Phosphodiesterase (PDE) Neurological Disease
    PF-04449613 is a selective PDE9A inhibitor with an IC50 of 22 nM[1]. PF-04449613 improved motor learning ability in a mouse model[2].
    PF-04449613
  • HY-163480
    PF-06835375

    		CXCR Inflammation/Immunology
    PF-06835375 is a selective, humanized CXCR5-targeting immunoglobulin G1 antibody. PF-06835375 depletes CXCR5-positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases .
    PF-06835375
  • HY-14464
    PF-00489791

    PF-489791

    		 Phosphodiesterase (PDE) Cardiovascular Disease Metabolic Disease
    PF-00489791 (PF-489791) is a potent inhibitor of phosphodiesterase 5A with IC50 of 1.5 nM. PF-00489791 can enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function .
    PF-00489791
  • HY-12883A
    PF-05198007

    		Sodium Channel Neurological Disease
    PF-05198007 is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor. PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771 .
    PF-05198007
  • HY-15490A
    PF-670462

    		Casein Kinase Neurological Disease
    PF-670462 is a selective CKI ε/δ inhibitor. PF-670462 effectively regulates the phase of the circadian rhythm .
    PF-670462
  • HY-118952
    PF-06456384

    		Sodium Channel Neurological Disease
    PF-06456384 is a highly potent and selective NaV1.7 inhibitor with an IC50 of 0.01 nM. PF-06456384 has the potential for formalin pain model research .
    PF-06456384
  • HY-19562A
    PF-06260933 hydrochloride
    4 Publications Verification

    		 MAP4K Inflammation/Immunology
    PF-06260933 hydrochloride is the hydrochloride form of PF-06260933 (HY-19562). PF-06260933 hydrochloride is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively .
    PF-06260933 hydrochloride
  • HY-123852
    PF-06764427

    		mAChR Neurological Disease
    PF-06764427 is a selective M1 muscarinic acetylcholine receptor positive allosteric modulator. PF-06764427 exhibits robust M1 agonist activity. PF-06764427 can be used in the research of Alzheimer's disease and schizophrenia .
    PF-06764427
  • HY-148353
    PF-06455943

    		LRRK2 Neurological Disease
    PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC50 value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .
    PF-06455943
  • HY-11088
    PF-3052334

    		HMG-CoA Reductase (HMGCR) Metabolic Disease
    PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC50 of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC50 values ​​of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia .
    PF-3052334
  • HY-14250
    PF-998425

    		Androgen Receptor Endocrinology
    PF-998425 is a potent, selective nonsteroidal androgen receptor (AR) antagonist with an IC50 of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research .
    PF-998425
  • HY-120510
    PF-04308515

    PF 4308515

    		 Glucocorticoid Receptor Interleukin Related PGC-1α Inflammation/Immunology
    PF-04308515 is a glucocorticoid receptor ligand. PF-04308515 inhibits IL-6, IFNγ production. PF-04308515 induces weak PGC1α interaction. PF-04308515 has antiinflammatory activities .
    PF-04308515
  • HY-13007A
    PF-3758309 hydrochloride

    PF-03758309 hydrochloride

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309 hydrochloride
  • HY-13007B
    PF-3758309 dihydrochloride

    PF-03758309 dihydrochloride

    		 PAK Apoptosis Cancer
    PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
    PF-3758309 dihydrochloride
  • HY-117879
    PF-4776548

    		HIV HIV Integrase Infection
    PF-4776548 is a highly potent HIV integrase inhibitor. PF-477654 blocks the process of integrating HIV viral DNA into the host cell genome. PF-4776548 is promising for research of AIDS .
    PF-4776548
  • HY-164519
    PF-7006

    		Apoptosis Mps1 Mitosis Cancer
    PF-7006 is an Mps1 kinase inhibitor with a Ki value of 0.27 nM and an IC50 value of 2.5 nM. PF-7006 interferes with cell cycle checkpoints by inhibiting the catalytic activity of Mps1, reducing histone H3 levels, and shortening the duration of mitosis, leading to apoptosis in cancer cells. Combined use of PF-7006 with Palbociclib (HY-50767) increases cancer cell tolerance to PF-7006. PF-7006 can be used for breast cancer research .
    PF-7006
  • HY-206852
    PF-06445974 precursor

    		Drug Intermediate Phosphodiesterase (PDE) Neurological Disease
    PF-06445974 precursor (Compound 28) is a nitro precursor and synthetic intermediate. PF-06445974 precursor can be used for the synthesis of PF-06445974 (HY-119190). PF-06445974 is a positron emission tomography (PET) compound that acts potently on PDE4B .
    PF-06445974 precursor
  • HY-P991668
    PF-06688992 Antibody

    		ADC Antibody Cancer
    PF-06688992 Antibody is an antibody targeting GD3. PF-06688992 Antibody can be used for the synthesis of the antibody-drug conjugate PF-06688992 (HY-P991668) .
    PF-06688992 Antibody

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: